Skip to main content

Labetalol (Monograph)

Drug class: beta-Adrenergic Blocking Agents
VA class: CV100
Chemical name: 2-Hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzamide monohydrochloride
Molecular formula: C19H24N2O3•HCl
CAS number: 32780-64-6

Medically reviewed by on Mar 3, 2022. Written by ASHP.


A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. For additional information, see the ASHP website [Web].


Selective α1- and nonselective β-adrenergic blocking agent (β-blocker).

Uses for Labetalol


Management of hypertension, alone or in combination with other classes of antihypertensive agents.

β-Blockers generally not preferred for first-line therapy of hypertension according to current evidence-based hypertension guidelines, but may be considered in patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes (ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, or thiazide diuretics). A 2017 ACC/AHA multidisciplinary hypertension guideline states that β-blockers used for ischemic heart disease that are also effective in lowering BP include bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, propranolol, and timolol.

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).

The 2017 ACC/AHA hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension. (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200


SBP (mm Hg)

DBP (mm Hg)









Hypertension, Stage 1




Hypertension, Stage 2




The goal of hypertension management and prevention is to achieve and maintain optimal control of BP. However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk. In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg. These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.

Other hypertension guidelines generally have based target BP goals on age and comorbidities. Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients compared with those recommended by the 2017 ACC/AHA hypertension guideline.

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors. ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg. Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP. Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to β-blockers. However, diminished response to β-blockers is largely eliminated when administered concomitantly with a thiazide diuretic.

Recommended by ACOG and other experts as an appropriate drug of choice in pregnant women who require antihypertensive therapy.

Severe Hypertension and Hypertensive Crisis

Used parenterally for immediate BP reduction in severe hypertension or hypertensive emergency; generally suitable for most hypertensive emergencies except when acute cardiac failure is present.

One of several recommended parenteral agents for use in the hospital setting to urgently lower BP in severely hypertensive pregnant women, including those with preeclampsia [off-label] or eclampsia [off-label].

Has been used for rapid reduction of BP in children and adolescents [off-label]with acute severe hypertension [off-label] and life-threatening symptoms.


Has been used alone in patients with pheochromocytoma to control hypertension and symptoms resulting from excessive β-receptor stimulation. However, some clinicians caution against use unless pretreatment with α-adrenergic blocking agents (e.g., IV phentolamine) has occurred. May be more effective when tumors predominantly secrete epinephrine rather than norepinephrine, and with sustained rather than paroxysmal hypertension. (See Pheochromocytoma under Cautions.)

Controlled Hypotension during Anesthesia

Treatment to produce controlled hypotension during anesthesia [off-label] to reduce bleeding resulting from surgical procedures.

Chronic Stable Angina

Long-term management of chronic stable angina pectoris.

β-Blockers are recommended as first-line anti-ischemic drugs in most patients with chronic stable angina; despite differences in cardioselectivity, intrinsic sympathomimetic activity, and other clinical factors, all β-blockers appear to be equally effective for this use.


Management of sympathetic overactivity syndrome associated with severe tetanus.

Labetalol Dosage and Administration


BP Monitoring and Treatment Goals

Severe Hypertension and Hypertensive Crisis


Administer orally, by direct IV injection, or by continuous IV infusion.

Oral Administration

Usually administered in 2 divided doses daily. If adverse effects (e.g., nausea, dizziness) occur and are intolerable (particularly with dosages ≥1.2 g daily), administration in 3 divided doses daily may improve patient tolerance and/or facilitate dosage titration.

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by slow, direct IV injection or by slow, continuous IV infusion.

Labetalol injection is intended for use in hospitalized patients.

Patients must be kept in a supine position during and for 3 hours after IV administration since symptomatic orthostatic hypotension is likely to occur if patients are tilted upward or allowed to assume an upright position. (See Hypotension under Cautions.)


For IV infusion, dilute labetalol injection to an appropriate concentration in a compatible IV infusion solution (e.g., add 200 mg of the drug to 160 mL of 5% dextrose injection to provide a solution containing 1 mg/mL).

Rate of Administration

Administer repeat doses by slow, direct IV injection over a 2-minute period at intervals of 10 minutes.

Administer diluted solutions by slow, continuous IV infusion with a controlled-infusion device to facilitate a desired rate of infusion.


Available as labetalol hydrochloride; dosage expressed in terms of the salt.

Pediatric Patients


Some experts have recommended an initial dosage of 1–3 mg/kg daily given in 2 divided doses. Increase dosage as necessary up to a maximum of 10–12 mg/kg or 1.2 g daily given in 2 divided doses.

Severe Hypertension†
Rapid Reduction of BP†
IV Injection

Children and adolescents: 0.2–1 mg/kg up to maximum of 40 mg per dose by direct IV injection.

IV Infusion

Alternatively, 0.25–3 mg/kg per hour by continuous IV infusion.



Initially, 100 mg twice daily, either alone or in combination with a diuretic.

Adjust dosage in increments of 100 mg twice daily every 2 or 3 days until optimum BP response is achieved.

For maintenance, manufacturers recommend a usual dosage of 200–400 mg twice daily. Manufacturers state that some adults with severe hypertension may require up to 1.2–2.4 g daily in 2 or 3 divided doses.

Some experts recommend a usual range of 100–400 mg twice daily. Rationale for lower dosage range is that it may be preferable to add another drug rather than continue to increase dosage.

Adjustment of labetalol dosage may be necessary when diuretic is initiated in a patient already receiving labetalol; optimum maintenance dosage is usually lower.

When transferring from other antihypertensive agents, start with usual initial labetalol dosage and gradually decrease dosage of the existing regimen.

Severe Hypertension and Hypertensive Crisis
IV Injection

Manufacturer recommends initial dose of 20 mg by slow (over 2 minutes), direct IV injection. Alternatively, some experts recommend initial dosage of 0.3–1 mg/kg (maximum 20 mg) by slow, direct IV injection every 10 minutes.

Higher initial doses (e.g., 1–2 mg/kg) have been administered, but the 20-mg dose is recommended to minimize adverse effects and the risks associated with too rapid reduction in BP.

May give additional doses of 40 or 80 mg at 10-minute intervals until the desired supine BP is achieved or up to a total cumulative dose of 300 mg.

IV Infusion

As an alternative to direct IV injection, manufacturer recommends initial rate of 2 mg/minute by continuous IV infusion; adjust rate according to the BP response.

Some experts recommend initial IV infusion rate of 0.4–1 mg/kg per hour; increase rate as needed up to 3 mg/kg per hour.

The usual effective, cumulative dose is 50–200 mg; up to 300 mg may be required.

Progressive, incremental IV infusion regimen (i.e., infusing 20, 40, 80, and 160 mg/hour for 1 hour at each dose level, or until the desired BP is achieved) has been used, and may result in more gradual BP reduction, minimizing adverse effects compared with repeated IV injections of the drug. Controlled comparisons of various IV administration methods are not available.

Oral (following IV dosage)

Discontinue IV therapy and initiate oral labetalol therapy (with tablets) when the supine DBP begins to increase.

Initially 200 mg, followed in 6–12 hours by an additional dose of 200 or 400 mg, depending on the BP response.

If necessary, oral dosage may be increased in usual increments at 1-day intervals while the patient is hospitalized (dosage range: 400–2400 mg daily administered in 2 or 3 divided doses).

Follow the usual oral dosage recommendations for subsequent outpatient dosage titration or maintenance dosing.

Severe Hypertension During Pregnancy (e.g., Preeclampsia†)
IV Injection

Initially, 10–20 mg by direct IV injection, followed by 20–80 mg every 20–30 minutes as needed for a maximum cumulative dose of 300 mg.

IV Infusion

As an alternative to direct IV injection, some experts recommend continuous IV infusion of 1–2 mg/minute.

Prescribing Limits

Pediatric Patients


Maximum 10–12 mg/kg or 1.2 g daily.

Severe Hypertension†
IV Injection

Children and adolescents: Maximum 40 mg per dose.



Maximum titration increment of 200 mg twice daily.

Severe Hypertension and Hypertensive Crisis

Maximum cumulative dose of 300 mg.

Severe Hypertension During Pregnancy (e.g., Preeclampsia†)

Maximum cumulative dose of 300 mg.

Special Populations

Hepatic Impairment

Dosage reduction may be necessary, but specific data are currently not available.

Renal Impairment

No dosage adjustment required in patients with mild to moderate renal impairment. In patients with severe renal impairment (i.e., Clcr <10 mL/minute) undergoing dialysis, once-daily dosing may be adequate.

Geriatric Patients


Adjustment in initial dosage not required. Maintenance dosage requirements are lower in most geriatric patients; 100–200 mg twice daily usually required.

Cautions for Labetalol




Hepatic Effects

Rarely, jaundice, hepatitis, severe hepatocellular injury, and elevated liver function test results have occurred; usually reversible following discontinuance, however, hepatic necrosis and death have been reported.

Discontinue immediately if jaundice or laboratory evidence of hepatic injury occurs.

Perform liver function tests at the first signs or symptoms of liver dysfunction (e.g., pruritus, dark urine, persistent anorexia, jaundice, right upper quadrant tenderness, flu-like syndrome).

Cardiac Failure

Possible precipitation of heart failure. Use contraindicated in patients with overt heart failure; may use cautiously in patients with well-compensated heart failure (e.g., those controlled with cardiac glycosides and/or diuretics). Use with caution in patients with inadequate cardiac function.

Adequate treatment (e.g., with a cardiac glycoside and/or diuretic) and close observation recommended if signs and symptoms of impending cardiac failure occur; if cardiac failure continues, discontinue therapy, gradually if possible.

Abrupt Withdrawal of Therapy

Abrupt withdrawal may exacerbate angina symptoms or precipitate MI in patients with CAD. Avoid abrupt discontinuance. Gradually decrease dosage over a period of 1–2 weeks, particularly in patients with ischemic heart disease and monitor patients carefully. If exacerbation of angina occurs or acute coronary insufficiency develops, reinstitute therapy promptly, at least temporarily, and initiate appropriate measures for the management of unstable angina pectoris.

Labetalol may be less likely than pure β-adrenergic blocking agents to produce adverse cardiovascular withdrawal reactions (e.g., angina, rebound hypertension) following abrupt withdrawal; angina pectoris has not been reported to date following discontinuance of labetalol.

Bronchospastic Disease

Possible inhibition of bronchodilation produced by endogenous catecholamines; use generally not recommended in patients with bronchospastic disease.

May use oral labetalol with caution in patients with nonallergic bronchospasm (e.g., chronic bronchitis, emphysema) who do not respond to or cannot tolerate other hypotensive agents; use smallest effective dose to minimize inhibition of endogenous or exogenous β-adrenergic agonist activity.

Do not use IV labetalol in patients with nonallergic bronchospasm at the usual therapeutic doses; has not been studied adequately.


Use with caution in patients with pheochromocytoma; oral labetalol may induce paradoxical hypertensive crisis. Use not recommended unless pretreatment with α-adrenergic blocking agents (e.g., IV phentolamine) has occurred.

Employ appropriate methods for determining urinary catecholamines if used in known or suspected pheochromocytoma. (See Specific Drugs and Laboratory Tests under Interactions.)

Diabetes and Hypoglycemia

Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia, BP changes), impaired glucose tolerance, delayed rate of recovery of blood glucose concentration following drug-induced hypoglycemia, altered hemodynamic response to hypoglycemia (possibly resulting in exaggerated hypertensive response), and impaired peripheral circulation.

Use with caution in patients with diabetes mellitus; dosage adjustment of the hypoglycemic agent may be necessary.

Major Surgery

Severe, protracted hypotension and difficulty in restarting or maintaining a heart beat have occurred during surgery in some patients receiving β-adrenergic blocking agents; however, withdrawal of β-adrenergic blocking agent prior to major surgery is controversial.

Effect of labetalol’s α-adrenergic activity in patients undergoing major surgery has not been evaluated, but several deaths have been reported with the use of the injection during surgery, including when used to control bleeding.

Synergistic hypotensive response occurs with concomitant use of IV labetalol and halothane anesthesia. (See Specific Drugs and Laboratory Tests under Interactions.)

Severely Elevated BP

Use caution when reducing severely elevated BP.

Use IV labetalol in hospitalized patients, and achieve the desired reduction over longest period of time compatible with the patient’s clinical status.

Avoid rapid or excessive reductions in SBP or DBP.

Serious adverse effects (e.g., cerebral infarction, optic nerve infarction, angina, and ischemic changes in the ECG) have been reported when severely elevated BP was reduced over several hours to up to 1 or 2 days with other hypotensive agents.

General Precautions


Orthostatic hypotension associated with loss of consciousness reported occasionally following IV administration and rarely following oral administration. Symptomatic orthostatic hypotension is likely to occur if supine patients are tilted upward or allowed to assume the upright position within 3 hours following IV administration.

If hypotension occurs, place the patient in Trendelenburg’s position, administer IV fluids, and/or temporarily discontinue administration of the drug.

Patients should remain supine during and for up to 3 hours after IV administration. Establish patient’s ability to tolerate an upright position before any ambulation (e.g., use of toilet facilities) is permitted; advise patient on how to proceed gradually to become ambulatory and observe at the time of initial ambulation.

Laboratory Tests

Monitor laboratory parameters at regular intervals in patients receiving long-term oral therapy.

Routine laboratory tests are usually not required before or after IV administration.

In patients with concomitant illnesses (e.g., impaired renal function), perform appropriate tests to monitor these conditions.

Possible Prescribing and Dispensing Errors

Ensure accuracy of prescription; similarity in spelling of labetalol hydrochloride and Lamictal (lamotrigine, an anticonvulsant agent) has resulted in dispensing errors. Errors may be associated with serious adverse events (e.g., status epilepticus, serious lamotrigine rash) in patients receiving the wrong drug.

History of Anaphylactic Reactions

Possible increased reactivity to a variety of allergens; patients may be less responsive to usual doses of epinephrine used to treat anaphylactic reactions.

Other Precautions

Shares the toxic potentials of β-adrenergic and postsynaptic α1-adrenergic blocking agents; observe the usual precautions of these agents.

Specific Populations


Category C.


Distributed into milk. Caution if used in nursing women.

Pediatric Use

Safety and efficacy not fully established; however, some experts have recommended dosages for hypertension based on clinical experience.

Geriatric Use

Orthostatic symptoms (e.g., orthostatic hypotension, dizziness, lightheadedness) are more likely in geriatric individuals than in younger adults; caution geriatric patients about the possibility of such symptoms.

A lower maintenance dosage may be required because of reduced elimination in geriatric patients. (See Geriatric Patients under Dosage and Administration.)

Hepatic Impairment

Use with caution; metabolism of the drug may be decreased. (See Special Populations under Pharmacokinetics.)

Renal Impairment

Elimination half-life may be increased in patients with severe renal impairment undergoing dialysis; once-daily dosing may be possible in these patients. (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Symptomatic orthostatic hypotension, dizziness or lightheadedness, fatigue, nausea, dyspepsia.

Drug Interactions

Specific Drugs and Laboratory Tests

Drug or Test



β-Adrenergic agonists

Labetalol may antagonize bronchodilating effects

Greater than usual dosages of β-adrenergic agonist bronchodilators may be required

Calcium-channel blocking agents (e.g., verapamil, diltiazem)

Possible additive therapeutic and adverse effects

Use concomitantly with caution


Absolute bioavailability of oral labetalol substantially increased, possibly via enhanced absorption or decreased first-pass hepatic metabolism

Carefully adjust labetalol dosage for optimal BP control with concomitant use


Increased hypotensive effect

Usually used to therapeutic advantage; careful dosage adjustments recommended

Glutethimide (no longer commercially available in the US)

Absolute bioavailability of oral labetalol decreased, possibly by increasing first-pass hepatic metabolism

Carefully adjust labetalol dosage for optimal BP control with concomitant use


Synergistic hypotensive effect; may result in large reduction in cardiac output and increase in central venous pressure

Adjust halothane concentration to control the degree and duration of hypotension; to minimize the risk of excessive hypotension, inspired halothane concentrations of ≥3% should not be used

Inform anesthesiologist if labetalol therapy is continued in a patient undergoing major surgery

Mibefradil (no longer commercially available in the US)

Slowing or complete suppression of SA node activity, with slow ventricular rates


Possible additive hypotensive effects and antagonism of the reflex tachycardia produced by nitroglycerin

Tricyclic antidepressants

Possible increased incidence of tremor

Tests for urinary catecholamines

Labetalol metabolites in urine may result in false-positive elevations of urinary free and total catecholamines, metanephrine, normetanephrine, and 3-methoxy-4-hydroxymandelic acid (vanillylmandelic acid, VMA) measured by fluorometric or photometric methods

When screening labetalol-treated patients suspected of having pheochromocytoma or when evaluating labetalol-treated patients with the tumor, use specific assay methods such as high-performance liquid chromatography (HPLC) with solid phase extraction to determine concentrations of catecholamines or their metabolites

Labetalol Pharmacokinetics



Rapidly and almost completely absorbed (i.e., 90–100%) from the GI tract following oral administration.

Undergoes extensive first-pass metabolism in the liver and/or GI mucosa. Absolute bioavailability is about 25%.


Following oral administration, hypotensive effect is generally apparent within 20 minutes to 2 hours, and maximal within 1–4 hours.

Maximum, steady-state BP response with twice-daily dosing occurs within 1–3 days.

Following slow, direct IV injection, hypotensive effect is apparent within 2–5 minutes, and usually maximal within 5–15 minutes.


Dose dependent; about 8–12 or 12–24 hours after a single 200- or 300-mg dose, respectively.

Following slow, direct IV injection, the hypotensive effect generally persists for about 2–4 hours, although a longer duration of effect (i.e., up to 24 hours) has been reported in some patients.


Delays absorption, but increases absolute bioavailability.

Special Populations

Relative bioavailability is increased in hepatic impairment.

First-pass metabolism may be reduced and bioavailability substantially increased in geriatric patients.



Following IV administration, rapidly and widely distributed into the extravascular space.

In animals, highest concentrations in the lungs, liver, and kidneys; only minimal amounts cross the blood-brain barrier.

Crosses the placenta; distributed into milk, principally as unbound labetalol.

Plasma Protein Binding

Approximately 50%.

Special Populations

In patients with impaired hepatic function, the apparent volume of distribution is decreased.



Following oral administration, extensively metabolized in the liver and possibly in the GI mucosa principally by conjugation with glucuronic acid, principally to O-alkylglucuronide and smaller amounts of O-phenylglucuronide and N-glucuronide.

Undergoes extensive first-pass metabolism in the liver and/or GI mucosa.

Elimination Route

Excreted in feces via biliary elimination (30% within 4 days) and in urine (55–60% within 24 hours), mainly as glucuronide conjugates.

Less than 5% of a dose is excreted unchanged in urine.


Biphasic or possibly triphasic; terminal half-life averages 2.5–8 hours. Manufacturers specify half-life of 5.5 or 6–8 hours following IV or oral administration, respectively.

Special Populations

Elimination may be reduced and half-life may be slightly increased in geriatric individuals.

Half-life apparently unchanged in individuals with renal or hepatic impairment, but may be increased in patients with severe renal impairment (i.e., Clcr <10 mL/minute) undergoing dialysis.

Not appreciably removed (<1% of a dose) by hemodialysis or peritoneal dialysis.





Well-closed containers at 2–30°C.

Protect tablets in unit-dose packages from excessive moisture.



2–30°C; protect from light and freezing.



Solution CompatibilityHID


Dextrose 5% in Ringer’s injection

Dextrose 5% in Ringer’s injection, lactated

Dextrose 2.5% in sodium chloride 0.45%

Dextrose 5% in sodium chloride 0.2, 0.33, or 0.9%

Dextrose 5% in water

Polysal in dextrose 5%

Ringer’s injection

Ringer’s injection, lactated

Sodium chloride 0.9%


Sodium bicarbonate 5%

Drug Compatibility
Y-Site CompatibilityHID


Amikacin sulfate


Amiodarone HCl

Ampicillin sodium


Butorphanol tartrate

Calcium gluconate

Cefazolin sodium


Chloramphenicol sodium succinate

Clindamycin phosphate

Clonidine HCl


Dexmedetomidine HCl

Diltiazem HCl

Dobutamine HCl

Dopamine HCl



Epinephrine HCl

Erythromycin lactobionate

Esmolol HCl


Fenoldopam mesylate

Fentanyl citrate

Gentamicin sulfate

Hetastarch in lactated electrolyte injection (Hextend)

Hydromorphone HCl

Hydroxyethyl starch 130/0.4 in sodium chloride 0.9%

Lidocaine HCl



Magnesium sulfate

Meperidine HCl


Micafungin sodium

Midazolam HCl

Milrinone lactate

Morphine sulfate

Nicardipine HCl


Norepinephrine bitartrate

Oxacillin sodium

Penicillin G potassium

Potassium chloride

Potassium phosphates


Ranitidine HCl

Sodium acetate

Sodium nitroprusside

Telavancin HCl

Tobramycin sulfate

Vancomycin HCl

Vecuronium bromide


Amphotericin B cholesteryl sulfate complex

Ceftaroline fosamil

Ceftriaxone sodium


Nafcillin sodium

Warfarin sodium


Heparin sodium


Advice to Patients


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Labetalol Hydrochloride


Dosage Forms


Brand Names



Tablets, film-coated

100 mg*

Labetalol Hydrochloride Tablets

200 mg*

Labetalol Hydrochloride Tablets

300 mg*

Labetalol Hydrochloride Tablets


Injection, for IV use

5 mg/mL*

Labetalol Hydrochloride Injection

AHFS DI Essentials™. © Copyright 2024, Selected Revisions March 3, 2022. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

Reload page with references included